UNSPSC 51112025: Trametinib

A type of kinase Inhibitor

UNSPSC 51112025 Trametinib is a Commodity code that encompasses the supply of this specific cancer treatment drug to state and local health systems, primarily through state health and human services agencies managing pharmacy benefits and patient access programs. State and local governments procure trametinib primarily through their pharmacy benefit programs, Medicaid agencies, and state employee health plans, often via direct manufacturer relationships or through group purchasing organizations and wholesalers that aggregate volume. The issuing bodies soliciting under this code are state health and human services commissions and related pharmacy benefit administrators that serve Medicaid beneficiaries, state employees, and covered retirees.

The Texas Health and Human Services Commission issued a Request for Information (RFI) on March 27, 2026, with a response deadline of April 3, 2026, seeking vendor capabilities and market intelligence for the Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program (Solicitation Number HHS0017013). The RFI solicits information from potential vendors about their capacity to enter direct contracts with self-insured employee group health plans and state agencies outside existing pharmacy benefit manager, group purchasing organization, and wholesaler arrangements, with emphasis on vendors' experience with direct contracting for self-insured employers and health plans in both private and government sectors within the past two years and their flexibility to negotiate contracts based on negotiated net pricing models without rebates. The state indicated this RFI is exploratory and will inform future formal procurement strategy before issuing a Request for Proposal with established financial and temporal parameters. No other recent state or local opportunities under this code appear in the available records.